Healthcare [ 12/13 ] | Medical Devices [ 109/164 ]
NASDAQ | Common Stock
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.
It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment.
In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation.
The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | 0.53 Decreased by -17.19% | 0.46 Increased by +15.22% |
| Feb 13, 24 | 0.80 Increased by +8.11% | 0.68 Increased by +17.65% |
| Nov 2, 23 | 0.74 Increased by +12.12% | 0.63 Increased by +17.46% |
| Aug 3, 23 | 0.50 Increased by +11.11% | 0.49 Increased by +2.04% |
| May 4, 23 | 0.64 Increased by +30.61% | 0.55 Increased by +16.36% |
| Feb 9, 23 | 0.74 Increased by +25.42% | 0.72 Increased by +2.78% |
| Nov 3, 22 | 0.66 Increased by +4.76% | 0.55 Increased by +20.00% |
| Aug 3, 22 | 0.45 Increased by +2.27% | 0.45 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 24 | 721.70 M Increased by +5.31% | 50.90 M Decreased by -33.46% | Increased by +7.05% Decreased by -36.82% |
| Dec 31, 23 | 854.50 M Increased by +20.62% | 205.50 M Increased by +110.99% | Increased by +24.05% Increased by +74.91% |
| Sep 30, 23 | 742.80 M Increased by +16.26% | 88.10 M Increased by 0.00% | Increased by +11.86% Decreased by -13.99% |
| Jun 30, 23 | 681.90 M Increased by +15.89% | 57.10 M Increased by +15.35% | Increased by +8.37% Decreased by -0.46% |
| Mar 31, 23 | 685.30 M Increased by +15.18% | 76.50 M Increased by +24.19% | Increased by +11.16% Increased by +7.82% |
| Dec 31, 22 | 708.40 M Increased by +3.64% | 97.40 M Increased by +28.67% | Increased by +13.75% Increased by +24.14% |
| Sep 30, 22 | 638.90 M Increased by +4.93% | 88.10 M Increased by +1.15% | Increased by +13.79% Decreased by -3.60% |
| Jun 30, 22 | 588.40 M Increased by +3.08% | 49.50 M Decreased by -14.06% | Increased by +8.41% Decreased by -16.63% |